Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of HIP1801 in Healthy Male Subjects
NCT04084197Phase 1Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- Dec 2018
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tamsulosin in benign prostatic hyperplasia (BPH) (4 arms), sponsored by Hanmi Pharmaceutical. Primary endpoints: Maximum Plasma Concentration at 48 hours and Area Under the Curve to Last Quantifiable Concentration at 48 hours. Started Dec 2018; status: completed.
02
Drugs
tamsulosin
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NCT04084197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04084197.